138 related articles for article (PubMed ID: 18076420)
1. Safety aspects of androgen treatment with 5alpha-dihydrotestosterone.
Sakhri S; Gooren LJ
Andrologia; 2007 Dec; 39(6):216-22. PubMed ID: 18076420
[TBL] [Abstract][Full Text] [Related]
2. Transdermal dihydrotestosterone treatment of 'andropause'.
de Lignieres B
Ann Med; 1993 Jun; 25(3):235-41. PubMed ID: 7687444
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio.
Yatkin E; Bernoulli J; Talvitie EM; Santti R
Int J Androl; 2009 Aug; 32(4):399-410. PubMed ID: 19515173
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
[TBL] [Abstract][Full Text] [Related]
5. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
6. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
7. Changes in testosterone and dihydrotestosterone levels in male rat accessory sex organs, serum, and seminal fluid after castration: establishment of a new highly sensitive simultaneous androgen measurement method.
Kashiwagi B; Shibata Y; Ono Y; Suzuki R; Honma S; Suzuki K
J Androl; 2005; 26(5):586-91. PubMed ID: 16088034
[TBL] [Abstract][Full Text] [Related]
8. Serum androgen bioactivity during 5alpha-dihydrotestosterone treatment in elderly men.
Raivio T; Tapanainen JS; Kunelius P; Jänne OA
J Androl; 2002; 23(6):919-21. PubMed ID: 12399539
[TBL] [Abstract][Full Text] [Related]
9. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
10. 5alpha-reductase isozymes and androgen actions in the prostate.
Zhu YS; Imperato-McGinley JL
Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.
Page ST; Lin DW; Mostaghel EA; Marck BT; Wright JL; Wu J; Amory JK; Nelson PS; Matsumoto AM
J Clin Endocrinol Metab; 2011 Feb; 96(2):430-7. PubMed ID: 21177791
[TBL] [Abstract][Full Text] [Related]
12. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
13. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.
Kunelius P; Lukkarinen O; Hannuksela ML; Itkonen O; Tapanainen JS
J Clin Endocrinol Metab; 2002 Apr; 87(4):1467-72. PubMed ID: 11932266
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA; Saad F
Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 5alpha-reductase blocks prostate effects of testosterone without blocking anabolic effects.
Borst SE; Lee JH; Conover CF
Am J Physiol Endocrinol Metab; 2005 Jan; 288(1):E222-7. PubMed ID: 15367394
[TBL] [Abstract][Full Text] [Related]
16. Androgen biosynthetic pathways in the human prostate.
Luu-The V; Bélanger A; Labrie F
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):207-21. PubMed ID: 18471780
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.
Ly LP; Jimenez M; Zhuang TN; Celermajer DS; Conway AJ; Handelsman DJ
J Clin Endocrinol Metab; 2001 Sep; 86(9):4078-88. PubMed ID: 11549629
[TBL] [Abstract][Full Text] [Related]
18. The influence of oestradiol on the metabolism of androgens by human prostatic tissue.
Bard DR; Lasnitzki I
J Endocrinol; 1977 Jul; 74(1):1-9. PubMed ID: 68984
[TBL] [Abstract][Full Text] [Related]
19. Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent.
Swerdloff RS; Wang C
Baillieres Clin Endocrinol Metab; 1998 Oct; 12(3):501-6. PubMed ID: 10332569
[TBL] [Abstract][Full Text] [Related]
20. One and the same androgen for all? Towards designer androgens.
Gooren LJ; Nguyen NT
Asian J Androl; 1999 Jun; 1(1-2):21-8. PubMed ID: 11225900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
